Severe asthma is a complex, heterogeneous disease that often remains uncontrolled despite available biologics, particularly in patients with non type 2 inflammation. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, has demonstrated broad efficacy across diverse severe asthma phenotypes, irrespective of eosinophil counts or biomarker levels. To further assess its real-world effectiveness, a study evaluated tezepelumab in 30 patients with severe asthma. The study found that after 6 months of tezepelumab treatment, asthma control improved significantly, with Asthma Control Test (ACT) scores increasing from 14.0 to 23.0.
Oral glucocorticoid use decreased from 11.6 mg/day to 4.2 mg/day, while annualized exacerbation rates fell from 4.0 to 0.5. Sinonasal symptoms improved, with Sinonasal Outcome Test-22 (SNOT-22) scores declining from 42.0 to 18.0. Blood eosinophil…
